All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Johnson & Johnson's subcutaneous Rybrevant (targeting EGFR), recommended by EU panel for non-small-cell lung cancer
Bispecific antibody, lung cancer, formulation - Read more

Roche's PATHWAY test approved by FDA as companion diagnostic for Enhertu (targeting HER2) in treating metastatic breast cancer patients
Antibody-drug conjugate, breast cancer, companion diagnostic - Read more

THE GOOD
Business Development

Vanda acquires global rights to AnaptysBio's imsidolimab (targeting IL-36R) psoriasis drug for $15M upfront, plus future milestone payments and royalties
Monoclonal antibody, generalized pustular psoriasis - Read more

EQL Pharma completes DKK 120M ($16.7M) purchase of four pharmaceutical assets from Medilink
Small molecule, depression, schizophrenia, necrotic wounds, anemia (iron deficiency) - Read more

PRESENTED BY TLDR BIOTECH
What would do with 5,000+ meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “5K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Pfizer showcases positive Ph3 data for Braftovi (kinase inhibitor) as part of drug combo targeting BRAF-mutated colorectal cancer
Small molecule, colorectal cancer - Read more

GH Research's inhaled mebufotenin (targeting serotonin receptors) positive Ph2 trial results good enough to “[pave] the way to…commercial success” in treatment-resistant depression
Small molecule, treatment-resistant depression, bipolar disorder, pospartum depression, psychedelic - Read more

Algiax Pharmaceuticals' touts a Ph2a win for non-opioid pain hopeful AP-325 (GABAA receptor modulator)
Small molecule, pain, pe­riph­er­al post-sur­gi­cal neu­ro­path­ic pain, non-opioid - Read more [Paywall]

Henlius Biotech publishes promising Ph2 results for serplulimab (targeting PD-1) plus bevacizumab (targeting VEGF) in hepatocellular carcinoma
Monoclonal antibody, hepatocellular carcinoma, cancer - Read more

United Therapeutics' UKidney (derived from gene-edited pig kidneys) cleared for Ph1 trial in end-stage renal disease patients, starting mid-2025
Organ transplant, renal disease, gene-edited organ - Read more

BriaCell Therapeutics showcases an “unprecedented clinical response” to their Bria-OTS immunotherapy in a Ph1/2a trial, lung metastasis resolution in metastatic breast cancer patient
Cell therapy, breast cancer, allogeneic cell therapy, personalized medicine - Read more

THE GOOD
Fundraises

Aplagon €7M ($7.21M) financing round, developing drug for peripheral arterial disease clinical trials
Modality not disclosed, peripheral arterial occlusive disease, chronic limb threatening ischemia - Read more

Enduro Genetics raises $12.4M Series A to scale biotech platform improving industrial microorganism productivity
Biomanufacturing, bioprocessing, synthetic biology - Read more

Dxcover $21.4M total funding, clinical diagnostics company expanding proprietary tech and market reach
Diagnostics, cancer screening, cancer diagnosis - Read more

AdvanCell $112M Series C, Australian radiopharmaceutical company expanding manufacturing and developing cancer treatments
Radiopharm, prostate cancer - Read more

Annovis Bio to-be-priced Public offering, developing neurodegenerative disease treatments with proceeds for clinical development
Small molecule, Alzheimer’s disease, Parkinson’s disease, neurodegenerative disease - Read more

BriaCell Therapeutics $3.05M public offering, gene-edited cell therapies targeting breast cancer
Cell therapy, breast cancer, allogeneic cell therapy, personalized medicine - Read more

Tectonic Therapeutic $185M PIPE financing, fusion proteins (relaxin receptor 1 agonists) in heart failure
Fusion protein, heart failure - Read more

Immunome $172.5M public offering, developing ADCs and radioligands against cancer
Antibody-drug conjugate, radiopharm, radioligand, cancer - Read more

89bio closes $287.5M public offering, developing therapies for liver and cardiometabolic diseases
Growth factor, metabolic dysfunction-associated steatohepatitis (MASH), hypertriglyceridemia - Read more

THE GOOD
IPOs

Sionna Therapeutics provides more precise figure for $150M IPO, offering shares at $16-18 per to fund cystic fibrosis ambitions
Small molecule, cystric fibrosis - Read more

THE GOOD
Partnerships

Purple Biotech, Icahn School of Medicine collaborate to study NK and T cell immunoregulation for cancer treatment
Cell therapy, cancer, research & development, T cell, Natural Killer (NK) cell - Read more

THE GOOD
Patient Access

Twelve new mpox vaccination sites open across England, expanding coverage beyond London, Brighton and Manchester
Vaccine, mpox (monkeypox), vaccine access - Read more

THE GOOD
Politics & Policy

Senators Warren and Wyden challenge RFK Jr.'s HHS nomination, citing antivaccine stance and Gardasil lawsuit conflicts of interest
Vaccine, anti-vax, conflict of interest - Read more

NSF resumes payments after five-day freeze, but researchers remain worried about funding stability and mixed messages
National Science Foundation, Research funding, research & development - Read more [Paywall]

THE GOOD
Product Launches

Helix launches registry combining genomic and health data from 15,000 GLP-1 patients to advance drug research
GLP, obesity, data registry, research & development - Read more

THE GOOD
Public Health

US confirms PEPFAR HIV aid program can continue during 90-day foreign aid pause under humanitarian assistance waiver
Humanitarian aid, human immunodeficiency virus (HIV) - Read more

THE GOOD
Strategic Plans

Biogen's research head emphasizes external partnerships and expansion beyond neurology to stay competitive
Big pharma strategy, research & development - Read more [Paywall]

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Business Development

Acelyrin returns autoimmune drug izokibep (targeting IL-17A) to Affibody after failed trials, ending partnership that began with $25M licensing deal in 2021
Small therapeutic protein, hidradenitis suppurativa, psoriatic arthritis, autoimmune - Read more

THE BAD
Company Shutdown

Epigenomic medicine company Omega Therapeutics announces imminent bankruptcy filing in the next few weeks
mRNA, cancer, carcinoma, solid tumor, epigenomics - Read more [Paywall]

THE BAD
Earnings & Finances

Activist investor Starboard Value urges Becton Dickinson pushes for life sciences unit spin-off after taking undisclosed stake in company
Activitist investor, divestiture - Read more

THE BAD
Layoffs

Thermo Fisher to lay off 300 more workers at Massachusetts viral vector sites, following previous cuts of 160 jobs
Cell & gene therapy, viral vector manufacturing - Read more

Charles River Laboratories closing Durham pathology facility, affecting 31 employees; work transfers to Maryland and Illinois locations.
CDMO, CRO, pathology facility - Read more [Paywall]

THE BAD
Market Reports

Despite 118 biologics losing patent protection, only 10% have biosimilars in development due to regulatory and market challenges
Drug development, commercialization, biosimilar - Read more

THE BAD
Politics & Policy

Letter supporting RFK Jr.'s HHS nomination includes discredited doctors and non-physicians among its nearly 800 signatories
HHS, political nomination - Read more

THE UGLY
Marketing

Novartis employee's LinkedIn likes of Cosentyx posts violated UK drug advertising rules, but company not held responsible
Drug marketing, drug advertising - Read more

THE UGLY
Politics & Policy

Trump's new tariffs on Canada, Mexico, and China could increase generic drug prices for Americans
Drug pricing, drug access, generic - Read more

Trump administration suspends Health IT Advisory Committee meetings, halting federal guidance on healthcare data and technology standards
Healthcare tech, public institution - Read more

Elon Musk claims Trump supports shutting down USAID, putting in jeopardy extensive US-backed medicines and healthcare supplies to developing nations
Humanitarian aid, global health, low- and middle-income countries - Read more

America Society for Microbiology removes diversity content from website in response to Trump's executive orders, sparking member outrage
DEI - Read more [Paywall]

CDC orders removal of gender-related terms from scientific papers following Trump executive order banning taxpayer-funded gender ideology promotion
DEI, gender issues, censorship - Read more

THE UGLY
Withdrawals & Recalls

Alvogen recalls fentanyl patches after packaging error creates overdose risk from accidentally stacked patches
Small molecule, pain, patch delivery, dosing error - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here